2 weeks Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates Zacks

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?